News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Shire plc Drug Replagal Slows Kidney Function Decline
April 9, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, April 8 (Reuters) - Shire's enzyme replacement drug Replagal slows the progression of kidney disease in men with Fabry disease, suggesting treatment should be started early, researchers said on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Weight loss
Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss
August 19, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
August 19, 2025
·
5 min read
·
Nick Paul Taylor
Sickle cell disease
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
August 18, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
